共 257 条
[11]
Dowsett M(2013)Challenges to the measurement of estradiol: an Endocrine Society position statement J Clin Endocrinol Metab 98 1376-1387
[12]
Forbes JF(2014)Measurement of estradiol–challenges ahead J Clin Endocrinol Metab 99 56-58
[13]
Bradley R(2013)Deficiencies in immunoassay methods used to monitor serum Estradiol levels during aromatase inhibitor treatment in postmenopausal breast cancer patients Springerplus 2 5-2016
[14]
Ingle J(2013)Predictors of recovery of ovarian function during aromatase inhibitor therapy Ann Oncol 24 2011-671
[15]
Aihara T(2007)Superiority of gas chromatography/tandem mass spectrometry assay (GC/MS/MS) for estradiol for monitoring of aromatase inhibitor therapy Steroids 72 666-372
[16]
Bliss J(2008)Prospective characterization of musculoskeletal symptoms in early stage breast cancer patients treated with aromatase inhibitors Breast Cancer Res Treat 111 365-2339
[17]
Boccardo F(2013)Aromatase inhibitor-induced modulation of breast density: clinical and genetic effects Br J Cancer 109 2331-700
[18]
Coates A(2011)Plasma letrozole concentrations in postmenopausal women with breast cancer are associated with CYP2A6 genetic variants, body mass index, and age Clin Pharmacol Ther 90 693-3286
[19]
Coombes RC(2010)Variation in anastrozole metabolism and pharmacodynamics in women with early breast cancer Cancer Res 70 3278-3797
[20]
Henry NL(2006)Comparison of methods to measure low serum estradiol levels in postmenopausal women J Clin Endocrinol Metab 91 3791-1508